otsgc-a24
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01227772)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- otsgc-a24
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03784040 | Phase 1 | Feb 21, 2019 | Bristol-Myers Squibb, National University of Singapore, OncoTherapy Science, Inc. |
| NCT01227772 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | National University of Singapore, Wakayama Medical University, Yonsei University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National University of Singapore | Academic/Hospital | 2 | 2 | 2 | 2010 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| OncoTherapy Science, Inc. | For profit | 1 | 0 | 1 | 2019 |
| Wakayama Medical University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1